ライフサイエンスコーパス: lymphocyte count

1 lucose concentration and a decrease in blood lymphocyte count.

2 s effect differs depending on CD4-positive T-lymphocyte count.

3 ng that coincided with normalization of CD3+ lymphocyte count.

4 B1 concentration is associated with absolute lymphocyte count.

5 across individuals were most correlated with lymphocyte counts.

6 easons may account for BL deficit at low CD4 lymphocyte counts.

7 ted with lower viral loads and higher CD4(+) lymphocyte counts.

8 tinine, or procalcitonin; or low platelet or lymphocyte counts.

9 ation of these changes with overall CD4(+) T lymphocyte counts.

10 but not to CD4 cell, total T cell, or total lymphocyte counts.

11 n CrAg-negative patients with similar CD4+ T-lymphocyte counts.

12 mycin resistance among patients with low CD4 lymphocyte counts.

13 undetectable viral loads and intact CD4(+) T-lymphocyte counts.

14 f GFP+ T cells showed normalization of their lymphocyte counts.

15 ngoing HIV replication but may increase CD4+ lymphocyte counts.

16 ntermittently based on peripheral blood CD3+ lymphocyte counts.

17 ients with an early hypoxia response but low lymphocyte counts.

18 I protein expression, and tumor-infiltrating lymphocyte counts.

19 phosphocholine with no effect on circulating lymphocyte counts.

20 , and negatively associated with post-stroke lymphocyte counts.

21 , and higher peak white blood cell (WBC) and lymphocyte counts.

22 x 1000 cells/muL [IQR, 5.6, 12.1]; P = .02), lymphocyte count (0.9 x 1000 cells/muL [IQR, 0.8, 1.1] v

23 .83 x 10(9) cells/L; P < 0.001), and similar lymphocyte counts (0.022 x 10(9) cells/L; P = 0.36), whe

24 2.1 ug/mL, P = .004) levels, and lower nadir lymphocyte counts (0.09 vs. 0.4 x 10(3) /uL, P = .006).

25 0.11 x 10(9) cells/L; P = 0.026), and higher lymphocyte counts (0.095 x 10(9) cells/L; P < 0.001).

26 2%), and > or = 50% reduction in circulating lymphocyte counts (11 of 22 patients; 50%).

27 ts/mL; P < .001), higher cerebrospinal fluid lymphocyte counts (122 vs 8 cells/muL; P < .001), and a

28 ficant (P < .05) increases in their adjusted lymphocyte counts (+126 cells/mm(3); approximately +7%),

29 e blood cell count (17 [19%]), and decreased lymphocyte count (14 [15%]).

30 onic, untreated malaria, NMI monkeys had a B lymphocyte count 23 times greater than that of PMI monke

31 in 267 (15%) of 1748 patients (median CD4+ T-lymphocyte count, 242 per cubic millimeter; interquartil

32 ), dyspnoea (29 [6%] vs ten [2%]), decreased lymphocyte count (29 [6%] vs nine [2%]), diarrhoea (18 [

33 ontrol subjects (odds ratio adjusted for CD4 lymphocyte count, 3.8; 95% confidence interval, 2.2-6.5)

34 , (2) is associated with a rapid recovery of lymphocyte counts, (3) reverses cytokine activation defi

35 cidofovir; CR = 13 (80%) vs 8 (35%); median lymphocyte count = 320/mul vs 910/mul; P < .05).

36 fection or disease had lower median absolute lymphocyte count (380 [IQR, 240-540] vs 940 [IQR, 551-12

37 To do so, we conducted a GWAS for lymphocyte count, a physiologic quantitative trait assoc

38 nt risk factors for mortality were low total lymphocyte count, advanced age, and male sex.

39 was no change in circulating eosinophil and lymphocyte counts after stenting in the allergy group (0

40 erum albumin and cholesterol concentrations, lymphocyte counts, age, body mass index (BMI), complicat

41 atients had Rai stage 0 CLL with an absolute lymphocyte count (ALC) < or = 10 x 10(9)/L; and 219 pati

42 dose total body irradiation, and an absolute lymphocyte count (ALC) </=100/mm(3) at the time of URI o

43 a sustained > or = 20% reduction in absolute lymphocyte count (ALC) and 11 (92%) of 12 patients with

44 d SLL differ in ways other than the absolute lymphocyte count (ALC) and evaluated treatment outcomes

45 Low absolute lymphocyte count (ALC) has potential to be a useful and

46 Absolute lymphocyte count (ALC) is considered a surrogate marker

47 We hypothesized that a lower absolute lymphocyte count (ALC) may alter HCV outcome after liver

48 absolute neutrophil count (ANC) and absolute lymphocyte count (ALC).

49 garding which lymphocyte parameter (absolute lymphocyte count [ALC] or B-cell count) and what thresho

50 on chemoprophylaxis, graft failure, absolute lymphocyte counts (ALCs), and mortalities were collected

51 Neither monocyte counts nor lymphocyte counts alone were associated with tuberculosi

52 Total lymphocyte count also predicted a subsequent CD4(+) T ce

53 loci of small effects influence variation in lymphocyte count and asthma susceptibility.

54 the immunologic parameters of blood CD4(+) T lymphocyte count and breadth of the HIV-1-specific CTL r

55 dy mass index, and (for those with HIV) CD4+ lymphocyte count and HIV RNA levels.

56 Cheaper, simpler alternatives to CD4 lymphocyte count and HIV-1 RNA detection for assessing t

57 -1 infection and correlated with both CD4(+) lymphocyte count and HIV-1 RNA level.

58 CD4(+) lymphocyte count and human immunodeficiency virus (HIV)

59 a more aggressive murine CLL as measured by lymphocyte count and inferior survival.

60 hese effects remained significant after CD4+ lymphocyte count and plasma HIV-1 RNA load at baseline w

61 -1 disease progression independently of CD4+ lymphocyte count and plasma HIV-1 RNA load, suggesting t

62 -lymphocyte recovery, 5 had persistent low B-lymphocyte count and remained on intravenous immunoglobu

63 , there was a modest rebound in the absolute lymphocyte count and serum complement levels, but substa

64 one that replaced CD4 cell count with total lymphocyte count and severity of anaemia (total lymphocy

65 s demonstrated both early reduction in blood-lymphocyte count and spleen size and prolongation of sur

66 were prospectively studied ex vivo for total lymphocyte count and subtype, NK cell phenotype, perfori

67 , fingolimod decreased both peripheral blood lymphocyte counts and brain Abeta levels, but at the low

68 rbidities, more systemic symptoms and higher lymphocyte counts and C-reactive protein levels.

69 d upper abdominal pain, as well as decreased lymphocyte counts and elevated liver aminotransferase le

70 e 46 patients who died were older, had lower lymphocyte counts and estimated glomerular filtration ra

71 of both conditions increases with lower CD4 lymphocyte counts and higher HIV-1 RNA levels.

72 The lead SNP was also associated with lower lymphocyte counts and in silico follow-up suggests a pot

73 anti-LTbetaR mAb significantly increased PP lymphocyte counts and intestinal IgA in PN fed-mice.

74 macrophages showed intact phagocytosis, and lymphocyte counts and proliferative capacity were normal

75 Serum CD4(+) T-lymphocyte counts and SIV copy numbers did not differ be

76 to determine the absolute T-lymphocyte and B-lymphocyte counts and the phenotypes of both T and B cel

77 r, time to normalization of peripheral blood lymphocyte counts and time to complete remission were sh

78 thylation, and hematoxylin and eosin-derived lymphocyte counts) and cell-specific benchmark datasets

79 esponses, CD4 and CD8 T-cell count, absolute lymphocyte count), and other transplantation-related fac

80 Disease duration, lymphocyte count, and azathioprine use were shown to be

81 gue, maculopapular rash, dyspnoea, decreased lymphocyte count, and decreased neutrophil count (two [3

82 count, the percentage of white blood cells, lymphocyte count, and interleukin 2R were affected by co

83 e bone sarcoma group, and anaemia, decreased lymphocyte count, and prolonged activated partial thromb

84 lower C3 levels, hemoglobin levels, absolute lymphocyte counts, and albumin levels, and a higher anti

85 f these measures and current or nadir CD4+ T-lymphocyte counts, and each measure was compared between

86 , chronic underlying condition, low absolute lymphocyte counts, and elevated creatinine levels were a

87 Viral load, lymphocyte counts, and HIV-1-specific CD8(+) cell immune

88 cantly higher white blood cell counts, lower lymphocyte counts, and increased C-reactive protein (CRP

89 respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation

90 linical, demographic, and exposure data, CD4 lymphocyte counts, and stool samples for detection of en

91 time led to decreases in platelet count and lymphocyte counts, and to increases in MCV and monocytes

92 unosuppression as measured by viral load and lymphocyte count; and viral reactivation patterns differ

93 CD4 + T-lymphocyte counts are used to assess CD4 + decline and t

94 rkedly reduced lymphocyte homing and reduced lymphocyte counts as a result of significantly decreased

95 ed with the magnitude of the increase in CD4 lymphocyte count, as were haplotypes in genes encoding i

96 ased with early infection, low maternal CD4+ lymphocyte count at recruitment, and frequent morbidity.

97 An increased lymphocyte count at the initiation of therapy was a pred

98 Immunity was assessed by CD4 T-lymphocyte counts at AIDS onset.

99 the herpes event nor the patients' absolute lymphocyte counts at baseline differed significantly bet

100 ls </=0.15 or 0.16 to 0.56 mug/mL had higher lymphocyte counts at day +30 and higher T-cell counts at

101 higher weight, and HIV viremia and lower CD4 lymphocyte counts at the time of HAV vaccination were as

102 t 6 months of HAV vaccination and higher CD4 lymphocyte counts at vaccination were inversely associat

103 After controlling for age, baseline CD4(+) lymphocyte count, baseline HIV-1 RNA level, and durable

104 or relapse was associated with baseline CD4 lymphocyte count, being 12.3% (9/73; 95% confidence inte

105 mia coincided with recovery of normal CD8+ T lymphocyte counts between days 48 and 76.

106 rane thickness, and BAL fluid neutrophil and lymphocyte counts but not eosinophil counts.

107 on had higher levels of troponin T and lower lymphocyte count, but elevated D-dimer and C-reactive pr

108 1), total WBC count by 139% (P = 0.006), and lymphocyte count by 106% (P = 0.02).

109 a significant reduction in peripheral blood lymphocyte count by up to 85%, which reversed within 3 d

110 r non-Hodgkin lymphoma (NHL), by age and CD4 lymphocyte count categories, were estimated using Poisso

111 , OFA therapy rapidly decreased the absolute lymphocyte count, CD20 expression by CLL cells, and seru

112 The total lymphocyte count, CD4+ and CD8+ T lymphocytes values wer

113 Activated CD4(+)/CD25(+) T-lymphocyte counts correlated negatively with serum conce

114 of IP-10/CXCL10, whereas CD4(+)/HLA-DR(+) T lymphocyte counts correlated positively with serum conce

115 imited data exist regarding whether relative lymphocyte count correlates with postdischarge outcomes

116 At week 8, absolute lymphocyte counts declined 49% from baseline in the grou

117 trophil counts were elevated (4.8x), whereas lymphocyte counts declined.

118 Lymphocyte counts decreased with BG-12.

119 A CD4 T-lymphocyte count determines eligibility for antiretrovir

120 rphologic changes and CD3(+) intraepithelial lymphocyte counts differed significantly from baseline t

121 Low CD4+ T-lymphocyte count, disease stage, performance status, ser

122 CD8, CD3, and total lymphocyte counts dropped concomitantly.

123 Low relative lymphocyte count during hospitalization for HF is an ind

124 should be aware of their patients' absolute lymphocyte counts during peg-IFN/RBV therapy; peg-IFN do

125 Despite differences in eosinophil and lymphocyte counts during the first 24 hours posttreatmen

126 CD4(+) T lymphocyte counts, eosinophil counts, and plasma HIV-1 R

127 two (3%) for acute kidney injury, decreased lymphocyte count, fatigue, neutropenia, and sepsis, and

128 In the prospective cohort, lymphocyte counts fell 90 minutes after reperfusion, pri

129 e events were anaemia (six [14%]), decreased lymphocyte count (five [12%]), prolonged activated parti

130 rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of

131 nt-naive or interferon-experienced, had CD4+ lymphocyte count >/=200 cells/microL or >/=14%, and plas

132 an HIV-1 RNA load <50 copies/mL and CD4(+) T lymphocyte count >400 cells/mm(3) were randomized to und

133 >20 000 cells/microL (aOR, 4.6), and to have lymphocyte counts >10 000 cells/microL (aOR, 7.2) (all P

134 ); (2) HIV-infected individuals whose CD4+ T-lymphocyte counts had always been more than 200/microL (

135 Low lymphocyte count has been shown to be an independent pro

136 d be used for diagnosis, and (3) whether any lymphocyte count has independent prognostic value after

137 ry OI prophylaxis among persons whose CD4+ T lymphocyte counts have increased in response to antiretr

138 ultivariate logistic regression model, nadir lymphocyte count, history of depression, and female sex,

139 herapy and level of immunodeficiency (CD4+ T lymphocyte count, human immunodeficiency virus [HIV] RNA

140 symptoms, respiratory rate, fever, absolute lymphocyte count, hypoalbuminemia, troponin level, and C

141 Lymphocyte counts, Ig levels, and anti-double-stranded D

142 Despite dramatic increases in CD4(+) lymphocyte counts, IL-2 did not enhance immunization res

143 A marked decrease in T- and B-lymphocyte counts immediately after transplant was follo

144 We assessed the prognostic value of total lymphocyte count, immune complex-dissociated p24 antigen

145 U.S.-born participants, but only with higher lymphocyte count in foreign-born participants.

146 ly anaemia in 14 (9%) patients and decreased lymphocyte count in nine (6%) patients.

147 Subsequent MR testing of lymphocyte count in the context of genetic correlation w

148 CD3+ lymphocyte count in the peripheral blood was determined

149 vity for S1P1 efficiently reducing the blood lymphocyte count in the rat were identified.

150 gonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat.

151 ently and dose dependently reduced the blood lymphocyte count in the rat.

152 ated adverse events, most commonly decreased lymphocyte count in three (2%) patients and anaemia in t

153 ense variant in South Asians associated with lymphocyte count in vivo and IL-7 secretion levels in vi

154 APH-2 levels were not correlated with lymphocyte count in vivo, consistent with the inability

155 inally, we mapped the phenotype of pulmonary lymphocyte counts in BALB x C57BL/6J F2 Cftr(tm1UNC) mic

156 ncy virus type 1 (HIV-1) RNA levels and CD4+ lymphocyte counts in HIV-infected patients improved afte

157 Despite higher plasma HIV levels and CD4 lymphocyte counts in infancy, HAART can result in timely

158 es into the blood, thus resulting in reduced lymphocyte counts in peripheral blood.

159 These compounds efficiently reduce blood lymphocyte counts in rats through 24 h after single dose

160 , as demonstrated by an increase in CD4(+) T-lymphocyte counts in recent clinical trials.

161 Despite significantly lower total T- and B-lymphocyte counts in SIV-infected sooty mangabeys than i

162 after cessation of natalizumab therapy, low lymphocyte counts in the CSF persisted.

163 pheral lymph nodes and moderate reduction in lymphocyte counts in the peripheral lymph nodes, despite

164 t trend for overall decrease in the absolute lymphocyte counts in TMG group (F=5.86, mixed model grou

165 d neutrophil numbers, associated with normal lymphocyte count, in peripheral blood and bone marrow, s

166 incidence rose steadily with decreasing CD4 lymphocyte counts; in contrast, BL incidence was lowest

167 Lymphocyte counts increased postnatally.

168 During antiretroviral therapy, CD4 lymphocyte count increases are modest in some patients d

169 s: plasma HIV-1 RNA level (viral load), CD4+ lymphocyte count, initiation of antiretroviral therapy (

170 iated with reduced increases in the CD4(+) T lymphocyte count, irrespective of plasma HIV RNA levels.

171 ciency virus-infected patients when the CD4+ lymphocyte count is < or =200 cells/mm3.

172 T) is recommended when the absolute CD4(+) T lymphocyte count is <200 cells/mm(3), and it should be c

173 ulin therapy, based on peripheral blood CD3+ lymphocyte counts, is safe and associated with low acute

174 The day-30 lymphocyte count (LC30) was strongly associated with out

175 stent lymphopenia was defined as an absolute lymphocyte count less than 1.2 cells/muLx10(3) present o

176 re, and/or acute renal injury), and absolute lymphocyte count less than or equal to 1,100 cells/muL.

177 articularly in those individuals with CD4(+) lymphocyte counts less than 50/mm(3).

178 Prolonged lymphopenia (absolute lymphocyte count < 1000 for >7 days) occurred only in ch

179 s (pOR = 3.14 (2.30, 4.29), I=48%), absolute lymphocyte count < 500 cells/mm (pOR = 6.29[3.56, 11.13]

180 openia was seen in 60% of patients (absolute lymphocyte count < 800/microL) with a median of 101 days

181 ll proportional hazards model, baseline CD4+ lymphocyte count <200, black race, other nonwhite race,

182 ent cytomegalovirus seropositivity, absolute lymphocyte count <300 cells/uL at D +30, and acute graft

183 ssion, comparable with that of cutoff CD4(+) lymphocyte count <350 lymphocytes/mm(3) and HIV-1 RNA le

184 Cell-mediated immunodeficiency (CD4(+) lymphocyte count <500 cells/mm(3)) was significantly ass

185 sed among HIV-seropositive women with CD4(+) lymphocyte counts <500 cells/mm(3) and among women with

186 to-crypt depth ratio; VHCD); intraepithelial lymphocyte counts; Marsh score; and patient-reported sym

187 median CD3+CD4+, CD3+CD8+, CD19+, and CD56+ lymphocyte counts measured at a median followup of 11.8

188 omen: </= 0.65 vs >0.05 mg/dL, P = .004) and lymphocyte count (men: </= 1700 vs >1700/muL, P = .04; w

189 tics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-

190 the curve >0.70), as were low albumin level, lymphocyte count, monocyte count, and ratio of periphera

191 Nadir lymphocyte count, not nadir neutrophil count, was indepe

192 ed an inverse association between IE and CD4 lymphocyte count (odds ratio [OR] for 200-499 cells/mm(3

193 Absolute lymphocyte count of <200 cells/mm(3) was associated with

194 Initiating HAART with a CD4+ lymphocyte count of <200 cells/mm3 was associated with a

195 values of 50 copies/mL or fewer and a CD4 T-lymphocyte count of 100 cells/mL or greater or patients

196 Eight patients with median lymphocyte count of 35.9 x 10(9)/L and median serum beta

197 ts with untreated HIV infection with a CD4 T-lymphocyte count of 500 cells/mL or greater.

198 bility of survival (P = .0032), and baseline lymphocyte count of at least 1,000/muL and response (CR/

199 HAART should be initiated at CD4+ lymphocyte counts of >200 cells/mm3.

200 gressed faster than those with baseline CD4+ lymphocyte counts of >350 cells/mm3 (P=.01).

201 ble virologic suppression with baseline CD4+ lymphocyte counts of >350 cells/mm3 (P=.40).

202 s (VCs) (<5,000 HIV-1 RNA copies/ml and CD4+ lymphocyte counts of >400 cells/mul) capable of soluble

203 ologic suppression, those with baseline CD4+ lymphocyte counts of <200 cells/mm3 tended to progress f

204 rogress faster than those with baseline CD4+ lymphocyte counts of 201-350 cells/mm3 (P=.09) and progr

205 progression between those with baseline CD4+ lymphocyte counts of 201-350 cells/mm3 and those with du

206 to 55 HIV-1-infected individuals with CD4+ T lymphocyte counts of 50-500 cells/microL.

207 as provided if participants had CD4-positive lymphocyte counts of fewer than 200 cells per muL.

208 ed with advanced extranodal disease and CD4+ lymphocyte counts of less than 200/mm3.

209 nfected individuals with a history of CD4+ T-lymphocyte counts of less than 50/microL, but with curre

210 d with Pneumocystis pneumonia were the total lymphocyte count one year before Pneumocystis, mTOR inhi

211 bstantial differences were found in absolute lymphocyte count or multiple immune cell subsets, includ

212 e no statistically significant reductions in lymphocyte count or serum immunoglobulin, anticardiolipi

213 d-maternal ratios were independent of CD4(+) lymphocyte counts or HIV-1 viral load.

214 dicated the need to change the threshold CD4 lymphocyte counts or HIV-RNA levels for initiation of th

215 of humoral immune recovery is inferred from lymphocyte counts or immunoglobulin levels and does not

216 l count (OR, 0.88; P = .049) and lower total lymphocyte count (OR, 0.76; P = .050) were associated wi

217 42, 95% CI 1.611-63.853, p = 0.014), reduced lymphocyte count (OR: 0.004, 95% CI 0.001-0.306, p = 0.0

218 of nausea and vomiting, decline in absolute lymphocyte count over several hours or days after exposu

219 P < .001); and larger CRAE with lower CD4+ T lymphocyte count (P = .04).

220 ortened survival was associated with low CD4 lymphocyte count (P<.0001), no ART (P<.0001), and crypto

221 all assay-alternatives to CD4 and RNA, total lymphocyte count (p<0.0001) and serum albumin (p=0.0107)

222 3), serious infection (P=0.0.018), and lower lymphocyte count (P=0.001) associated with increased mor

223 01) and neutrophil (P < 0.01) counts and low lymphocyte counts (P < 0.01).

224 erval, 0.0-4.5%) among those with higher CD4 lymphocyte counts (p < 0.01).

225 One week after transfer, lymphocyte counts peaked (median of 14.3 x 10(3) cells//

226 Naive lymphocyte counts peaked around 1 year, whereas most mem

227 VB analysis did not correlate with the lymphocyte count prior to lymphocytotoxic therapy; howev

228 , heart failure, diabetes mellitus, relative lymphocyte count, prothrombin time, peripheral artery di

229 correlated significantly with current CD4+ T-lymphocyte count (r = - 0.344, P = 0.022).

230 ationship between level of infection and CD4 lymphocyte count (R = -0.73; P < 0.001).

231 24 antigen level correlated with both CD4(+) lymphocyte count (r=-0.34; P<.0001) and HIV-1 RNA level

232 nant women according to age, baseline CD4(+) lymphocyte count, receipt of HAART, and date of cohort e

233 Lymphocyte counts recovered to LLN after a single course

234 e donor chimerism (P = .04) and faster total lymphocyte count recovery (P = .04) without any statisti

235 ical studies, a positive correlation between lymphocyte count recovery after autologous transplantati

236 sis are associated with the magnitude of CD4 lymphocyte count recovery during antiretroviral therapy.

237 Absolute lymphocyte count remained below preoperative level for 1

238 uring the peak of viremia, the milk CD4(+) T lymphocyte counts remained unchanged, despite active vir

239 Despite absolute lymphocyte counts remaining between 500-1000/mm(3) , his

240 0.90] of mm Hg per 1 SD genetically elevated lymphocyte count, respectively), which was directionally

241 subgroups based on current and nadir CD4+ T-lymphocyte counts (severely immunosuppressed, immune rec

242 ristics: age, beta-2 microglobulin, absolute lymphocyte count, sex, Rai stage, and number of involved

243 Lower circulating leukocyte, neutrophil, and lymphocyte counts show the anti-inflammatory effects of

244 95% CI, 0.01-4.8; P = .35), intraepithelial lymphocyte counts (standardized mean difference, 0.21; 9

245 iovascular risk factors, HIV viral load, CD4 lymphocyte count, statin use, antihypertensive use, and

246 e more likely to present with lower CD4(+) T-lymphocyte counts than MSM who do not attend church.

247 accompanied by a transient rise in absolute lymphocyte count that is asymptomatic and probably the r

248 Patients in groups 1 and 2 had CD4+ T-lymphocyte counts that were similar to those in patients

249 The serum absolute lymphocyte count, the presence of tumor-infiltrating den

250 A total lymphocyte count threshold <1000/uL offered the best pre

251 odeficiency virus type 1 (HIV-1) load, total lymphocyte count (TLC), body mass index (BMI), and hemog

252 participants with marked lymphopenia (total lymphocyte count [TLC] </=1200 cells/muL).

253 Two had transient decrease in lymphocyte count to normal, whereas in 5, disease progre

254 ne metagene expression values and histologic lymphocyte counts to quantify immune infiltration and as

255 Geometric mean recovery time (GMRT) of total lymphocyte counts to the lower limit of the normal range

256 The pre-ART viral load and CD4+ lymphocyte count trajectories were also comparable betwe

257 t reduction of white blood cell and absolute lymphocyte count up to 1 year posttransplant.

258 art HIV diagnostic technologies for CD4(+) T lymphocyte count, viral load measurement, and drug resis

259 ifference in change in total intraepithelial lymphocyte count was -12.73% (95% CI -77.57-52.12); nomi

260 onal Prognostic Index scores; the median CD4 lymphocyte count was 112/mm(3) (range, 19/mm(3) to 791/m

261 retroviral therapy (ART), and the median CD4 lymphocyte count was 131 cells/microL.

262 The mean (SD) age was 35 (6.9) years, CD4 T-lymphocyte count was 236 (139) and log10 plasma HIV RNA

263 l load of <400 copies/mL), and median CD4+ T-lymphocyte count was 459 cells/mm(3) (interquartile rang

264 d of <400 copies/mL, and the median CD4(+) T-lymphocyte count was 471 cells/microL.

265 Twenty-four hours post-CLP, the lymphocyte count was higher in the P-DIE than in the P-L

266 The median CD4 lymphocyte count was highest with pathogen-free diarrhea

267 4] x 10(9) cells/L, p = 6.93 x 10(-57)), but lymphocyte count was less consistent (0.016 [0.007, 0.02

268 In this group, CD4+ T-lymphocyte count was low, despite a significantly lower

269 0.7+/-0.6 vs. 2.1+/-1.0, P=0.0004); however, lymphocyte count was recovered and was back to reference

270 cific T cell responses, in addition to total lymphocyte counts, was also observed.

271 a T-cell leukemia showing rapidly rising PB lymphocyte counts, was the only tumor type expressing th

272 were incidentally found to have low CD4(+) T-lymphocyte counts, we investigated whether plateletphere

273 < .001), and lower CD4 cell count and total lymphocyte count were associated with bacteremic dissemi

274 Prolactin levels and absolute lymphocyte count were measured on days 1, 3, 7, 14, and

275 ral load and sustained decreases in CD4(+) T lymphocyte count were observed, especially in subjects w

276 White blood cell and absolute lymphocyte count were significantly lower in alemtuzumab

277 HIV-1 infection and low CD4(+) lymphocyte count were strongly associated with HPV infec

278 CD4(+) T-lymphocyte counts were <200 cells per microliter in 0/20

279 Mean (SD) baseline and nadir CD4+ lymphocyte counts were 553(217) and 177(117) cells/micro

280 Low lymphocyte counts were associated with wide QRS duration

281 CSF lymphocyte counts were explored in 151 MS patients recru

282 Throughout the 100 weeks, CD4+ lymphocyte counts were higher in the OZ1 group.

283 Current and nadir (lowest previous) CD4+ T-lymphocyte counts were identified for each subject.

284 onors, respectively (P = .019), and CD8(+) T-lymphocyte counts were low in 0/20, 4/20, and 11/20 dono

285 marrow tumor only occurred if circulating B-lymphocyte counts were persistently less than 0.001 x 10

286 Circulating lymphocyte counts were reduced in 18 of 26 patients with

287 Lymphocyte counts were retrospectively analyzed in 1,377

288 tastases, and serum hemoglobin, albumin, and lymphocyte counts were significant for predicting surviv

289 Total lymphocyte counts were significantly lower in the RIT gr

290 Submucosal mast cell, neutrophil, and lymphocyte counts were similar in both groups.

291 A higher lymphocyte count when ribavirin therapy was initiated wa

292 eater virologic suppression and higher CD4 T-lymphocyte counts when managed by a multidisciplinary te

293 ould be influenced by low systemic and local lymphocyte counts, which lead to impaired lung injury re

294 ed genes, and changes in monocyte/neutrophil/lymphocyte counts, while TIV elicited similar but lower

295 dentified a potential causal relationship of lymphocyte count with systolic BP and diastolic BP (caus

296 itive and potentially causal relationship of lymphocyte count with systolic BP and diastolic BP.

297 rate demonstrated a positive association of lymphocyte count with urine albumin-to-creatinine ratio.

298 toward progressive modest increases in CD4+ lymphocyte counts with GM-CSF treatment at 16 weeks (med

299 istribution phenomenon, we correlated serial lymphocyte counts with volumetric changes in lymph node

300 group significantly depended on infiltrating lymphocyte counts, with patients who showed both an earl